Search

Home > New FDA Approvals > 130 - Osimertinib for first-line NSCLC plus EGFR Mutation Test v2 test; OVOMotion™ shoulder arthroplasty system; Fiscal Year 2019 budget request comments
Podcast: New FDA Approvals
Episode:

130 - Osimertinib for first-line NSCLC plus EGFR Mutation Test v2 test; OVOMotion™ shoulder arthroplasty system; Fiscal Year 2019 budget request comments
Category: Science & Medicine
Duration: 00:09:33
Publish Date: 2018-04-20 06:00:00
Description:

April 20, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

1:20 US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer https://www.prnewswire.com/news-releases/us-fda-approves-tagrisso-osimertinib-as-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-300632643.html

3:43 Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO® https://www.prnewswire.com/news-releases/roche-expands-indication-for-cobas-egfr-mutation-test-v2-as-a-companion-diagnostic-with-tagrisso-300632648.html

05:31 Arthrosurface Gains FDA Clearance of OVOMotion™ Shoulder Arthroplasty System https://www.prnewswire.com/news-releases/arthrosurface-gains-fda-clearance-of-ovomotion-shoulder-arthroplasty-system-300632592.html

07:12 Remarks from FDA Commissioner Scott Gottlieb, M.D. on Fiscal Year 2019 budget request for FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604826.htm

Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0